Bigger India

Why Ranbaxy Chose Not to Fight US Drug Adulteration Charges

With $1 billion turnover from US, it was important to settle the case, says CEO and MD Arun Sawhney.

Leave a Reply

Your email address will not be published. Required fields are marked *